BC
BIOS Capital Management, LP
Concentrated strategyMomentum followerHigh-turnover trader
Total reported value
$52.9M
Reporting period: 2026-03-31 · Number of holdings: 10
BIOS Capital Management, LP disclosed 10 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $52.9M and a quarterly turnover rate of 73.4%.
Personality snowflake
- Concentration
- 100
- Portfolio Stability
- 73.36
- Momentum/Contrarian
- 100
- Sector conviction
- 0
- Diversification
- 12
- Sizing Uniformity
- 87.54
Recent moves
Add IRD
0.0% $9.4M
Trim ACTU
0.0% -$34.0M
Add RNTX
+17.2% $615.8K
Trim LTRN
-14.4% -$1.9M
Trim CGTX
0.0% -$3.5M
Trim INAB
-33.8% -$344.6K
Holdings Map
New buyAddUnchangedTrim
Top 10 holdings by weight
Full holdings list this quarter
Showing top 6 holdings (of 10 total)
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ACTU | Actuate Therapeutics INC | Stock-Other | 52.09% | -22.35% | — | |
| 2 | IRD | Opus Genetics INC | Stock-Other | 31.70% | +22.74% | — | |
| 3 | CGTX | Cognition Therapeutics INC | Stock-Other | 8.63% | -1.17% | — | |
| 4 | RNTX | Rein Therapeutics INC | Stock-Other | 4.87% | +2.50% | +17.25% | |
| 5 | LTRN | Lantern Pharma INC | Stock-Other | 2.24% | -1.46% | -14.37% | |
| 6 | INAB | In8bio INC | Stock-Other | 0.47% | -0.25% | -33.78% |
Reported value over time
Sector allocation
Not enough sector-mapped data yet
Sector allocation over time
Quarterly history
Holding changes this quarter
BIOS Capital Management, LP's most significant position changes for 2026-03-31: Add: Rein Therapeutics INC (RNTX) — shares +17.25%; Trim: Lantern Pharma INC (LTRN) — shares -14.37%; Trim: In8bio INC (INAB) — shares -33.78%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IRD | Opus Genetics INC | +22.7% | — | Unchanged |
| 2 | RNTX | Rein Therapeutics INC | +2.5% | +17.25% | Add |
| 3 | INAB | In8bio INC | -0.3% | -33.78% | Trim |
| 4 | CGTX | Cognition Therapeutics INC | -1.2% | — | Unchanged |
| 5 | LTRN | Lantern Pharma INC | -1.5% | -14.37% | Trim |
| 6 | ACTU | Actuate Therapeutics INC | -22.4% | — | Unchanged |
FAQ
What is BIOS Capital Management, LP and what type of investor is it?
BIOS Capital Management, LP is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $52.9M, spread across 10 disclosed positions.
What are BIOS Capital Management, LP's largest equity positions?
Based on the latest 13F filing, BIOS Capital Management, LP's top holdings by market value are:
1. Actuate Therapeutics INC (ACTU) — $27.5M (52.1%)
2. Opus Genetics INC (IRD) — $16.8M (31.7%)
3. Cognition Therapeutics INC (CGTX) — $4.6M (8.6%)
4. Rein Therapeutics INC (RNTX) — $2.6M (4.9%)
5. Lantern Pharma INC (LTRN) — $1.2M (2.2%)
What changes did BIOS Capital Management, LP make in its most recent portfolio filing?
In the latest reported quarter, BIOS Capital Management, LP made 3 notable position adjustments: 0 new positions were initiated, 1 existing holdings were added to, 2 positions were partially reduced, and 0 were completely exited. The largest of these moves: Add: Rein Therapeutics INC (RNTX) — shares +17.25%; Trim: Lantern Pharma INC (LTRN) — shares -14.37%; Trim: In8bio INC (INAB) — shares -33.78%
What sectors does BIOS Capital Management, LP focus on?
Sector breakdown data is not yet available for BIOS Capital Management, LP. Check back after the next 13F processing cycle.